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Rapid and dependable methods for isolating human pluripotent stem cell (hPSC) populations are urgently needed 
for quality control in basic research and in cell-based therapy applications. Using lectin arrays, we analyzed glyco-
proteins extracted from 26 hPSC samples and 22 differentiated cell samples, and identified a small group of lectins 
with distinctive binding signatures that were sufficient to distinguish hPSCs from a variety of non-pluripotent cell 
types. These specific biomarkers were shared by all the 12 human embryonic stem cell and the 14 human induced 
pluripotent stem cell samples examined, regardless of the laboratory of origin, the culture conditions, the somatic cell 
type reprogrammed, or the reprogramming method used. We demonstrated a practical application of specific lectin 
binding by detecting hPSCs within a differentiated cell population with lectin-mediated staining followed by fluores-
cence microscopy and flow cytometry, and by enriching and purging viable hPSCs from mixed cell populations using 
lectin-mediated cell separation. Global gene expression analysis showed pluripotency-associated differential expres-
sion of specific fucosyltransferases and sialyltransferases, which may underlie these differences in protein glycosy-
lation and lectin binding. Taken together, our results show that protein glycosylation differs considerably between 
pluripotent and non-pluripotent cells, and demonstrate that lectins may be used as biomarkers to monitor pluripo-
tency in stem cell populations and for removal of viable hPSCs from mixed cell populations. 
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Introduction
Human pluripotent stem cells (hPSCs) hold great 
promise for the treatment of human disease. These cells, 
which include human embryonic stem cells (hESCs) and 
induced pluripotent stem cells (hiPSCs), have two defin-
ing characteristics: the ability to self-renew indefinitely 
and the ability to differentiate into all cell types in the 
body. These qualities make hPSCs potential sources of 
large quantities of any cell type that can then be used 
for research and clinical applications, including disease 
modeling, drug screening, and cell replacement therapies 
for degenerative disease. However, a major concern for 
the use of hPSCs for all of these applications, especially 
for transplantation therapy, is the need for a pure popula-Lectin biomarkers of pluripotency
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tion of the cell type of interest. For cell therapy, residual 
undifferentiated hPSCs are potentially tumorigenic and 
thus must be removed [1]. In addition, use of impure cell 
populations can lead to inaccurate evaluations of drug ef-
ficacy and toxicity, differentiation potential, or other cel-
lular responses. Thus, reliable techniques for identifying 
pluripotent cells in populations are critically needed, not 
only for purification of differentiated hPSCs intended for 
clinical use, but also for validation of cell identity in ba-
sic research. There are a few antibodies that target pluri-
potency-associated cell surface antigens [2-7] and can be 
used to identify pluripotent cells in preparations of viable 
cells. But the generation of cell type-specific surface an-
tibodies is challenging, and optimization of cell purifica-
tion strategies would be enhanced by additional methods 
to identify, isolate, and remove pluripotent cells.
Pluripotency-associated antigens on the cell surface 
are often glycoproteins or glycolipids [2-4, 7], suggest-
ing that specific glycosylation patterns of proteins may 
be a hallmark of pluripotency. Glycosylation is the most 
widespread post-translational modification, occurring in 
over 50% of all cellular proteins [8]. Dynamic changes in 
protein glycosylation have been observed in tumorigen-
esis [9, 10], cell differentiation [11], cell adhesion [12], 
and host-pathogen interactions [13, 14], and communica-
tions between the intracellular signaling pathways and 
the extracellular environment are frequently mediated 
through oligosaccharide modifications of membrane-
bound proteins and their ligands [15, 16]. Though the 
importance of protein glycosylation in hPSCs has been 
suggested by several previous studies using cell biology 
and biochemical methods [16-18], information regard-
ing the global protein glycosylation status in a broad 
spectrum of hPSCs and their differentiated derivatives is 
lacking. Advances in microarray technologies have led to 
the development of lectin microarrays, which use lectins 
as probes to determine the relative amounts of specific 
glycan marks among different cell populations. These 
arrays make sensitive, high-throughput characterization 
of protein glycosylation feasible [19, 20]. The utility of 
lectin arrays for characterizing cells has been illustrated 
by two very recent studies [21, 22].
To identify lectins that are useful for identifying and 
separating hPSCs in mixed cell populations, we system-
atically profiled the glycoproteins in a broad spectrum 
of cells (Table 1) using lectin microarrays. These cells 
included hESCs, human induced pluripotent stem cells 
(hiPSCs), human dermal fibroblast (HDF) cells, human 
epidermal melanocytes (HEM), malignant melanoma 
cell lines, and other differentiated cell types. We identi-
fied a subset of lectins that distinguish pluripotent cells 
from non-pluripotent cells, regardless of cell origins and 
culture methods. In addition, we demonstrated the feasi-
bility of using a pluripotency-associated lectin to identify 
and remove viable pluripotent cells from heterogeneous 
populations containing differentiated cells. We also show 
correlations between expression of specific glycosyl-
transferases and pluripotency-associated protein glycosy-
lation.
Results
Identification of pluripotency-associated lectins
To identify lectins recognizing glycoproteins on the 
cell surface, we first used the lectin arrays to determine 
the lectin-binding patterns for the hydrophobic protein 
fraction. This fraction should be highly enriched for 
membrane-bound proteins because of the abundance 
of hydrophobic amino-acid residues in transmembrane 
domains, while hydrophilic proteins are more likely 
to be intracellular proteins. The profiling results were 
subjected to a supervised clustering analysis, and the 13 
lectins that showed highly significant differential bind-
ing between pluripotent and non-pluripotent cell types 
(P < 0.05, t-test) were identified for a “priority lectin” 
list (Supplementary information, Table S1). As shown 
in Supplementary information, Figure S1, hierarchical 
clustering based on the glycan signatures of hydrophobic 
proteins determined by these 13 priority lectins shows 
that the pluripotent cells clustered together, regardless 
of their type (hESC or hiPSC), source (somatic cell type 
used for reprogramming), or location of the lab of origin 
(La Jolla or Kyoto). With the exception of human leu-
kocytes, whose profile overlapped with the pluripotent 
cells, the tested non-pluripotent cells all clustered sepa-
rately. The shared profiles between hPSCs and human 
leukocytes may be due to the frequent presence of sialyl-
Lewis X glycan on the leukocyte surface; reactivity of 
fucose-specific and sialic acid-specific lectins has been 
reported in studies of human leukocytes [23, 24].
To validate the reliability of glycomic profiling as a 
means of identifying pluripotent cells, we challenged 
the system by comparing nearly genetically identical 
pluripotent and non-pluripotent cells. We compared two 
newly reprogrammed hiPSC clones (iPS1.HEMd and 
iPS2.HEMd) with their somatic cell line of origin, a pri-
mary human melanocyte line (HEMd). These cell lines 
have identical genomes except for the presence of inte-
grated sequences from the reprogramming factors used 
to generate the hiPSCs. The hiPSC lines were identified 
as pluripotent by immunofluorescence staining, differ-
entiation in vitro, and teratoma generation (Supplemen-
tary information, Figure S2a and S2b). When analyzed 
and clustered with the other samples, the hiPSC lines www.cell-research.com | Cell Research
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Table 1 List of cultured cells used in the study
Sample name  Registry name
1  Note
2
Human embryonic stem cells
BG01  BG01  Passage 67
3
BG02  BG02  Passage 46
3 
BG03  BG03  Passage 55
3
WA01  WA01  Passage >50
3
WA01   WA01  Passage 35
4
WA07  WA07  Passage 35
3
WA09   WA09  Passage 31
4
WA09P90_MEF/MAN  WA09  Passage 90; MEF, manual passage
3, 5
WA09P90_MG/MAN  WA09  Passage 90; Matrigel, manual passage
3, 5 
WA09P90_MEF/ACC  WA09  Passage 90; MEF, enzymatic passage
3, 5 
WA09P42_MG/ACC  WA09  Passage 42; Matrigel, enzymatic passage
3, 5 
WA09P90_MG/ACC  WA09  Passage 90; Matrigel, enzymatic passage
3, 5 
Induced pluripotent stem cells from human dermal fibroblasts (HDF)
201B2 P24  CiRA201i-B2HDF  Passage 24
4
201B6 P24  CiRA201i-B6HDF  Passage 24
4
201B7 P24  CiRA201i-B7HDF  Passage 24
4 
201B7 P78  CiRA201i-B7HDF  Passage 78
4
253G1 P24  CiRA253i-G1HDF  Passage 24
4
253G4 P24  CiRA253i-G4HDF  Passage 24
4
iPS2.HDF-ALS275  TSRI02i-ALS275  Passage 60; ALS patient 275
3, 5 
iPS5.HDF-ALS285  TSRI05i-ALS285  Passage 24; ALS patient 285
3, 5 
iPS8.HDF-ALS284   TSRI08i-ALS284  Passage 22; ALS patient 284
3, 5 
iPS1.HDF  TSRI001i-HDF  Passage 37; Matrigel, enzymatic passage
3, 6
iPS7.HDF  TSRI007i-HDF  Passage 62; Matrigel, enzymatic passage
3, 6
iPS11.HDF  TSRI011i-HDF  Passage 58; Matrigel, enzymatic passage
3,6
Induced pluripotent stem cells from human epidermal melanocytes (HEM)
iPS1.HEMd  TSRI001i-HEMD  Passage 3
3
iPS2.HEMd  TSRI002i-HEMD  Passage 3
3
Cells used for reprogramming
aHDF   NA  HDF passage 6
4
HDF51  NA  HDF passage 9; Sciencell
3
HDF-ALS275  NA  HDF passage 7; ALS patient 275
3, 8
HDF-ALS284  NA  HDF passage 6; ALS patient 284
3, 8
HEMd  NA  HEM passage 5; Sciencell
3
Other cell types
SKMEL2  NA  Human melanoma cells, passage 45; ATCC
3
MALME3M  NA  Human melanoma cells, passage 36; ATCC
3
SKMEL5  NA  Human melanoma cells, passage 41; ATCC
3
UACC257  NA  Human melanoma cells, passage 10; Charles River
3
WA07P34MNPD29  WA07  Motor neuron progenitor cells differentiated from 
    WA07 cells
7
HREpic  NA  Human renal epithelial cells, passage 12; Sciencell
3
HSkMC  NA  Human skeletal muscle cells; passage 15; Sciencell
3
MEF  NA  Mouse embryonic fibroblast
3
1Name of cell line submitted to International Stem Cell Registry (U. Mass.).
2Passage number, culture methods, source of cells.
3Samples cultured in Loring laboratory.
4Samples cultured in Yamanaka laboratory.
5Provided by I Garitaonandia, Loring laboratory.
6Provided by I Slavin, Loring laboratory.
7Provided by H Keirstead, UC Irvine.
8Cells provided by Solutions for ALS (SALSa).Lectin biomarkers of pluripotency
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were grouped with the other pluripotent cells, while the 
primary melanocytes were classified as non-pluripotent 
(Figure 1A). To explore this further, hESCs (WA07) 
were differentiated into motor neuron progenitor cells 
using a well-established protocol [25]. The glycomic 
profile of the neuronal cells was then compared to that of 
the undifferentiated hESCs. Similar to the somatic cell-
hiPSC comparison, the differentiated motor neuron pro-
genitors clustered with the non-pluripotent cells and the 
undifferentiated hESCs cells with the same genome were 
grouped with the pluripotent cells (Figure 1A).
Detection of hPSCs and separation of hPSCs from differ-
entiated cells using pluripotency-associated lectins
From the 13 priority lectins, we selected 3 lectins, 
AOL, TJA-II, and UEA-1, that showed consistently 
strong signals in pluripotent cells (Figure 1B). To deter-
mine whether these lectins are specifically bound to the 
surfaces of hPSCs, we performed immunofluorescence 
staining on a mixed population of HDFs and hESCs 
using biotinylated lectins. The UEA-I lectin bound se-
lectively to pluripotent hESCs that are also positive for 
POU5F1 (also known as OCT4) and SSEA-4, two well-
established markers of pluripotency (Figure 1C). Similar 
staining patterns were also observed when the cells were 
incubated with biotinylated AOL and biotinylated TJA-II 
(Supplementary information, Figure S2c and S2d).
Since UEA-I showed the lowest reactivity with non-
pluripotent cells among the three selected lectins in the 
array analysis (Figure 1B) and fluorescence staining 
(Figure 1C and Supplementary information, Figure S2c 
and S2d), we tested the utility of lectins for separation of 
cells from mixed hPSC/differentiated cell populations by 
using a magnetic submicron bead separation procedure 
mediated by the UEA-I lectin. The general procedure to 
test hPSC-purging efficiency is illustrated in Figure 2A. 
As shown in Figure 2B and Supplementary information, 
Figure S3, depletion of hPSCs from mixed populations 
was very efficient; non-pluripotent (calcein-positive) 
cells comprised up to 99.5% of the uncaptured cell popu-
lation recovered from mixtures of WA09 cells and HDF 
or HEMd. For pluripotent R-Olig2 cells mixed with their 
non-pluripotent, differentiated derivatives, the purity of 
calcein-positive cells in the uncaptured cell population 
after the cell separation was about 95% (Figure 2B and 
Supplementary information, Figure S3f). These data 
strongly suggested that the lectins identified in this study 
could be a useful tool to purge hPSCs from a variety of 
differentiated cell types. 
To determine whether viable hPSCs could be isolated 
from mixed cell populations using lectins, a mixture of 
WA09 hESCs and fibroblasts was sorted using UEA-
I-linked magnetic beads. Results are shown in Supple-
mentary information, Figure 3a and 3b. Both bound and 
unbound populations were replated in culture dishes and 
stained with SSEA-4 to identify pluripotent cells in each 
fraction. In the viable cell population captured from the 
mixed population by UEA-I beads, calcein fluorescence 
(fibroblasts) was mostly absent, and most cells were 
positive for the pluripotency-associated markers SSEA4 
(Supplementary information, Figure S3b), POU5F1, 
NANOG, SOX2, Tra-1-60, and Tra-1-81 (Supplementary 
information, Figure S3c). The captured cells retained the 
ability to differentiate in vitro into all three germ layers 
(Supplementary information, Figure S3c). In contrast, 
most of the cells in the unbound fraction were fibroblasts 
(calcein-positive) and negative for SSEA-4 (Supplemen-
tary information, Figure S3a), indicating that the lectin-
Figure 1 Glycomic profiling of hPSCs and non-pluripotent cells using lectin microarrays with validation of lectin binding to 
hPSCs. (A) Hydrophobic proteins isolated from the cells were labeled and analyzed by lectin microarrays. Supervised hi-
erarchical clustering based on the array data of 13 priority lectins for the hydrophobic proteins of 26 samples of hPSCs (12 
samples of hESC and 14 samples of hiPSCs, including 2 clones of hiPSCs newly reprogrammed from human primary mel-
anocytes) and 22 samples of mammalian non-pluripotent cells (4 samples of HDFs, 4 samples of human melanoma cells, 1 
sample of primary human melanocytes, 1 sample of mouse embryonic fibroblasts, 2 samples of human leukocytes, 1 sample 
of human adult brain tissue, 1 sample of human fetal liver tissue, 1 sample of motor neuron precursor cells differentiated 
from WA07 cells, 1 sample of cardiac muscle, 1 sample of adipose tissue, 2 samples of skeletal muscle, 1 sample of adrenal 
gland, 1 sample of lung tissue, and 1 sample of renal epithelium) was performed using the NIA Array Analysis Tool. In the 
dendrogram, samples acquired at the Scripps Research Institute and Kyoto University are indicated by yellow and blue solid 
squares, respectively. Pluripotent and non-pluripotent cells are indicated by red dots and green dots, respectively. Some of 
the samples are highlighted by colored lines to emphasize their relationships. Purple line: WA07 cells. Pink line: motor neu-
ron precursor cells differentiated from WA07 cells. Black line: human primary melanocytes. Orange line: hiPSCs derived from 
primary melanocytes. (B) Fluorescent intensity of UEA-1, AOL, and TJA-II lectin binding with hydrophobic cell extracts based 
on microarray data. RFU: relative fluorescence units. (C) WA09 cells were spiked into a cell suspension of HDFs to create a 
mixed cell population. The cells were fixed on adhesion slides and then subjected to staining with anti-POU5F1 and SSEA-4 
antibodies as well as biotinylated UEA-I lectin. WA09 cells with expression of pluripotent biomarkers POU5F1 or SSEA-4 are 
indicated by arrowheads and positive UEA-I staining. Insets, magnified images of the double-positive cells.www.cell-research.com | Cell Research
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bound beads effectively separated viable pluripotent and 
non-pluripotent cells.
To quantify the sensitivity and specificity of the bind-
ing of UEA-I lectin in hPSCs, we used UEA-1-mediated 
fluorescence staining in conjunction with flow cytom-
etry analysis. Approximately 95% of WA09 cells were 
strongly positive for UEA-I binding, while less than 5% 
of HDF cells were dimly positive (Figure 3A). We found 
that UEA-I was rendered easily removable from the cell 
surface by washing in a fucose-containing buffer (data 
not shown). Flow cytometric analysis of multiple hP-
SCs lines co-stained with SSEA-4 antibody and UEA-I 
lectin (Figure 3B) indicated that UEA-I is a comparable 
biomarker to SSEA-4 for detecting cellular pluripotency 
with high sensitivity and specificity.
Comparison of lectin-binding patterns in hydrophobic 
and hydrophilic proteins extracted from hPSCs and dif-
ferentiated cells
The results shown so far describe the glycocompo-
nents of hydrophobic proteins expressed in hPSCs. To 
determine whether the glycomic profiles of the hydro-
philic protein fraction also reflected the pluripotent state 
of cells, we selected hydrophilic protein samples extract-
ed from 11 samples of hPSCs and 10 samples of non-
pluripotent cells for profiling on the lectin arrays. As was 
observed for the hydrophobic proteins, hierarchical clus-
tering of the glycomic profiles of hydrophilic proteins 
separated the pluripotent cells from the non-pluripotent 
cells (Supplementary information, Figure S4a). 
Comparison of the profiles of hydrophilic and hydro-
phobic proteins (Supplementary information, Figure S4) 
revealed that the glycans that differed between hPSCs 
and non-pluripotent cells were different in the two pro-
tein fractions. In the hydrophobic fraction, fucose-specif-
ic (UEA-I, AOL, AAL and TJA-II) and sialic acid-specif-
ic (SNA, SSA and TJA-I) lectins bound preferentially to 
the proteins isolated from the hPSCs. In the hydrophilic 
fraction, lectins that have high affinity for glycans con-
taining N-acetylgalactosamine (GalNAc), such as BPL, 
Jacalin, WFA, MAP, and HPA, preferentially interacted 
with the hPSC proteins (Supplementary information, 
Figure S4c). Our results suggest that glycoproteins from 
both the hydrophilic and the hydrophobic fractions could 
be used to discriminate between pluripotent and non-
pluripotent cells. We observed an interesting trend in the 
non-pluripotent cells: cells of similar lineages tended to 
be clustered more closely together in their hydrophobic 
protein glycan profiles than in their hydrophilic protein 
glycan profiles (e.g., melanocytes with melanoma, fi-
broblasts from different sources). We detected no such 
lineage-associated patterns among the pluripotent cells.
Figure 2 Lectins can be used to purge pluripotent cells from 
mixed populations. (A) Diagram of depletion experiments. 
hESCs (unlabeled) were mixed with different Calcein AM-
labeled differentiated cells (green) at a ratio of 1:1. Cells were 
incubated with UEA-I magnetic beads. The cells captured by 
the magnetic beads were isolated and the unbound, eluted cells 
were analyzed for Calcein AM fluorescence by flow cytometry. 
(B) Results of depletion experiments using mixtures of WA09 
and HDFs, WA09 and HEMd, and R-Olig2 hESCs and their 
NSC derivatives. For each sample, the unreacted mixture and 
the mixture reacted with beads showed about 50% Calcein AM-
positive cells because half of the cells in the 1:1 mixture were 
labeled. After magnetic separation of the beads, nearly all of 
the remaining cells were Calcein AM-positive, indicating that the 
pluripotent cells had been removed from the mixture. www.cell-research.com | Cell Research
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Figure 3 Lectin binding to pluripotent cells. (A) WA09 hES cells were incubated with streptavidin-AF 555 only or with strepta-
vidin-AF 555 and biotinylated UEA-I. Human dermal fibroblasts (HDFs) were incubated with streptavidin-AF 555 and biotiny-
lated UEA-I. Fluorescence intensity was analyzed by flow cytometry. As expected, WA09 cells incubated with streptavidin-AF 
555 alone (negative controls) as well as HDFs incubated with streptavidin-AF 555 and biotinylated UEA-I both showed mini-
mal levels of fluorescence, while WA09 cells incubated with streptavidin-AF 555 and biotinylated UEA-I showed high levels of 
fluorescence. (B) WA09, R-Olig2, and iPS1.HDF pluripotent cells were incubated with secondary antibody and streptavidin-
AF 555 only (negative control; upper right) or SSEA-4 antibody, secondary antibody, UEA-I biotinylated lectin and streptavid-
in-AF 555 (treated cells, lower right), and subjected to flow cytometry. The negative control cells show minimal fluorescence, 
but more than 95% of the treated cells in all three tested hPSC lines show either double-positive or double-negative staining. 
This indicates that biotinylated UEA-I lectin can be used in flow cytometry and that it labels a similar percentage of pluripotent 
cells as SSEA-4, a well-recognized biomarker of human cell pluripotency.
Expression analysis of fucosyltransferase and sialyl-
transferase genes in hPSCs and differentiated cells
The differences in glycoprotein signatures between 
pluripotent and non-pluripotent cells suggested that dif-
ferential expression of glycotransferase genes may be in-
volved in the establishment and maintenance of distinct 
glycoprotein profiles. To address this idea, we examined 
relative mRNA expression levels of 13 fucosyltrans-
ferase genes and 19 sialyltransferase genes using array-
based gene expression analysis of 22 samples of hPSCs 
and 27 samples of non-pluripotent cells. The hierarchi-
cal clustering of the tested samples revealed that hPSCs 
share similar expression patterns of fucosyltransferase 
and sialyltransferase genes, which differ considerably 
from those expressed by non-pluripotent cells (Figure 
4A). Differential gene expression analysis indicated that Lectin biomarkers of pluripotency
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FUT1, FUT2, FUT10, ST3GAL2, and ST6GAL1 genes 
had higher expression levels in the hPSCs, whereas 
POFUT1, POFUT2, ST3GAL1, ST3GAL3, ST3GAL4, 
ST3GAL5, ST3GAL6, ST6GALNAC6, ST8SIA1, and 
ST8SIA4 genes were preferentially expressed in the non-
pluripotent cells (Figure 4B). Consistent with our data, 
the major products generated by the fucosyltransferases 
FUT1 and FUT2, which were highly expressed in pluri-
potent cells, are known to bind specifically to the lectin 
UEA-I that we used to discriminate pluripotent from 
non-pluripotent cells ([26], Lectin Frontier Database at 
http://riodb.ibase.aist.go.jp/rcmg/glycodb/LectinSearch). 
Also, the major product generated by the sialyltrans-
ferase ST6GAL1 has a high affinity for other lectins, 
SNA, SSA, and TJAI, that showed preferential binding 
to pluripotent cells ([27], Lectin Frontier Database). 
While the expression levels of mRNAs may not directly 
reflect the abundance or activity of these glycosyltrans-
ferases, they suggest that changes in glycosyltransferase 
gene expression may be involved in the regulation of 
pluripotency and differentiation of human cells.
Discussion
In this study, we identified lectin biomarkers for pluri-
potent cells, and show that specific lectins can be used 
to identify, sort, and separate human pluripotent cells 
(hPSCs) in mixed populations with differentiated cells. 
Our results suggest that lectins can be integrated into 
strategies for purifying populations of hPSC-derived dif-
ferentiated cells destined for drug screening, studies of 
human disease, and cell replacement therapy. It is espe-
cially critical to purge undifferentiated hPSCs from cell 
preparations used for clinical transplantation, because 
the greatest concern for using hPSC-derived cells is that 
residual undifferentiated cells may be tumorigenic. To 
our knowledge, this is the first report showing that lectins 
can be used to isolate and remove hPSCs from mixed 
cell populations. Historically, lectins have been known 
for their affinity for glycans on many different cell types. 
The idea that lectins may react with pluripotent cells was 
initiated in early 1980s by studies showing the ability of 
lectins to bind to or kill embryonal carcinoma and germ 
cell tumor cells [28-32]. However, a comprehensive, 
large-scale analysis of lectin binding in hPSCs was not 
tangible until recently [21, 22]. Consistent with our find-
ings, hPSC-preferential binding of lectins that have high 
affinity to glycans containing sialic acid α2-6 and fucose 
α1-2 structures was observed in a study using a large 
quantity but relatively limited types of cell samples [21]. 
The presence of unique fucosylation signatures on pro-
teins in hPSCs has also been detected and associated with 
the pluripotent status of the cells by proteomic analysis 
[17]. Although differential lectin binding to proteins ex-
tracted from pluripotent stem cells using array-based ap-
proaches has been shown by two recent reports, neither 
study attempted to apply this information for developing 
methods for isolation of pluripotent cells from mixed 
populations or for purging differentiated populations of 
residual pluripotent cells [21, 22].
The data presented here show that the fucose-specific 
lectin UEA-I is a potential tool for isolating viable hPSCs 
with sustained pluripotency from heterogeneous popula-
tions (Supplementary information, Figure S3c). Current-
ly, separation of cell subpopulations relies in large part 
on antibodies to cell surface epitopes, and our research 
suggests that cell type-specific lectins can complement 
existing methods. In some cases, lectins may offer cer-
tain advantages over antibodies. They can be easily re-
moved from cells without damaging them, by adding an 
oligosaccharide or monosaccharide that competes with 
the glycan to which the lectin binds. Also, since lectins 
are significantly less expensive than antibodies, they may 
offer advantages for procedures in which cost is an im-
portant factor, such as large-scale hPSC purifications for 
cell therapy and drug screening.
Cell surface antibodies are often species-specific; for 
example, SSEA-4 antibody, a commonly used antibody 
for human PSCs, does not recognize mouse PSCs, and 
instead binds to differentiated mouse cells. In contrast, 
our data suggest that the same lectins that can be used 
to identify human PSCs can also be used for pluripotent 
cells from other species, including mouse (Supplementary 
information, Figure S5) and a diversity of other animals 
(not shown). Thus, for labs working with pluripotent 
cells from more than one species, the same lectin can be 
used for all pluripotency monitoring and isolation ap-
plications. Also, the cross-species lectin recognition of 
PSCs implies that certain types of glycosylation are hall-
marks of the pluripotent state; this suggests that studies 
of specific glycosylation may reveal novel information 
about transitions that occur during cellular reprogram-
ming and differentiation of PSCs.
Many of the lectins that showed preferential asso-
ciation with the hydrophobic proteins of hPSCs bind 
to fucosylated and sialylated glycans, suggesting that 
fucosylation and sialylation are common characteristics 
of PSC glycoproteins. Fucosylation and sialylation are 
two common types of glycosylation on the cell surface 
[26, 33], and these modifications have been shown to be 
critical in normal embryogenesis and somatic stem cell 
differentiation [16, 34-36]. Our gene expression analysis 
suggests that the protein fucosylation and sialylation sig-
natures in hPSCs may be due to differential expression www.cell-research.com | Cell Research
Yu-Chieh Wang et al.
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Figure 4 Gene expression profiles of human fucosyltransferases and sialyltransferases in hPSCs and non-pluripotent cells. 
(A) RNA was hybridized to Illumina arrays as described in Materials and Methods. The heat-map representation of the array 
data indicates the relative expression levels of specific glycosyltransferases in the cells. The results of the hierarchical clus-
tering of expression patterns in different cell types are illustrated as a dendrogram. Pluripotent and non-pluripotent cells are 
indicated by red and green dots, respectively. (B) The expression levels of 13 fucosyltransferases and 19 sialyltransferases 
in 22 samples of hPSCs (8 samples of hiPSCs and 14 samples of hESCs) and 27 samples of human non-pluripotent cells (14 
samples of organ tissues and 13 samples of cultured cells). The fluorescence intensities of each gene probe were averaged, 
log2-transformed and plotted. Columns, mean of log2-transformed fluorescence intensities; bars, standard deviation. *P < 0.01, 
fold change of expression > 1.4 (differential expression analysis performed by GenePattern using non-transformed values of 
intensity).Lectin biomarkers of pluripotency
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of specific fucosyltransferases and sialyltransferases in 
pluripotent cells. This supports the idea that post-transla-
tional glycosylation of cell surface proteins plays a role 
in the regulation of transitions between pluripotent and 
differentiated states that occur during reprogramming of 
somatic cells and differentiation of pluripotent cells. It 
is also interesting to note that hydrophilic glycoproteins, 
which are primarily intracellular proteins, also differed 
between pluripotent and differentiated cells. In particular, 
we observed differences in GalNAc-containing glyco-
conjugates; GalNAc usually acts as a core component of 
O-linked glycans, which are frequently found on serine 
and threonine residues in mucins and other secreted pro-
teins [37]. This suggests that O-linked glycosylation of 
serine and threonine in secreted proteins may be involved 
in the regulation of pluripotency, possibly by controlling 
autocrine or paracrine feedback loops.
Our work shows that lectin-based approaches are sen-
sitive and reliable tools to detect pluripotency-associated 
protein glycosylation. The most important application 
of lectins to the basic and clinical applications of hP-
SCs is likely to be removal of residual pluripotent cells 
from differentiated populations, and to our knowledge, 
our report is the first to show the feasibility of using 
lectins to remove undifferentiated pluripotent cells from 
mixed populations. Additionally, our work suggests that 
glycosylation changes may also provide clues to the 
mechanisms underlying reprogramming, pluripotency, 
and differentiation. We anticipate that the use of lectins 
as biomarkers will become a valuable tool for stem cell 
research, especially for translational applications such as 
purifying precursor populations or purging pluripotent 
cells from differentiated populations.
Materials and Methods
Cell culture
Cells obtained from the Loring lab, HDF51 and MEF cells, 
were cultured in DMEM containing 10% fetal bovine serum (FBS) 
at 37 °C. HEMd cells (ScienCell Research Laboratories, Carlsbad, 
CA, USA) were cultured in melanocyte medium (MelM; ScienCell 
Research Laboratories). The methods for culturing all the hPSCs 
provided by the Loring lab are listed in Supplementary informa-
tion, Table S2.
Cells obtained from the Yamanaka lab, adult HDF (aHDF) cells 
harvested from a human skin biopsy specimen, were cultured in 
DMEM containing 10% FBS, 50 units/ml penicillin and 50 µg/ml 
streptomycin. The methods for culturing all the hPSCs provided by 
the Yamanaka lab are listed in Supplementary information, Table 
S2.
Dr Hans Keirstead generously provided WA07 hESCs and 
WA07P34MNPD29 motor neuron progenitors differentiated from 
WA07 hESCs. The culture methods and the differentiation proto-
cols were previously reported [25].
Generation of hiPSCs
In the Loring lab, HEMd and HDF cells were seeded onto a 
six-well plate at a density of 1.5 × 10
6 cells per well one day be-
fore viral transduction. Cells were given equal volumes of viral su-
pernatants containing retroviruses carrying each of four pMX ex-
pression vectors for POU5F1, Sox2, Klf4, MYC genes [38] on day 
0 and day 1. On day 2, the transduced cells were transferred onto 
radiation-inactivated MEF feeder cells at a density of 1 × 10
4 cells 
per well of a six-well plate and cultured in DMEM/F12 media with 
l-glutamine containing 20% KnockOut™ Serum Replacement, 
100 µM non-essential amino acids, 100 µM β-mercaptoethanol 
(all from Life Technologies, Carlsbad, CA, USA), 12 ng/ml FGF2, 
and 500 µM valproic acid (VPA; both from Stemgent, Cambridge, 
MA, USA) at 37 °C. The medium was changed every day for 14 
days before VPA was withdrawn. The hiPSC colonies were manu-
ally picked 3 weeks after transduction and transferred onto new 
plates covered by the MEF feeder cells. In the Yamanaka lab, the 
hiPSCs were generated from aHDF cells using a previously re-
ported reprogramming protocol [38].
Directed neural differentiation of hPSCs
R-Olig2 hESCs were subcloned from BG01 hESCs [39] and 
cultured in StemPro
® hESC serum-free medium (Life Technolo-
gies). Non-pluripotent, SOX1-positive neural stem cells (NSCs) 
were differentiated from R-Olig2 hESCs as previously described 
[40] with minor modifications. Briefly, hESC colonies were har-
vested using collagenase and cultured in suspension as embryoid 
bodies (EBs) for 8 days in hESC medium without bFGF. EBs were 
then cultured for an additional 2-3 days in suspension in neural 
induction medium containing DMEM/F12 with Glutamax, non-es-
sential amino acids, N2, and bFGF prior to attachment on Geltrex-
coated cell culture dishes. After 2-3 days of adherent culture, neu-
ral rosettes were formed and manually isolated, dissociated into 
single cells with Accutase, and replated onto culture dishes coated 
with Geltrex (Life Technologies). The NSC population was then 
expanded in StemPro
® NSC serum-free medium (Life Technolo-
gies) containing bFGF (20 ng/ml) for 8-10 passages. Expression 
of NSC biomarkers SOX1 and NESTIN in the cells was confirmed 
by immunofluorescence staining.
Glycomic profiling of proteins isolated from human tissues 
and cultured cells
The proteins of human tissues and cultured pluripotent and non-
pluripotent cells were fractionated using CelLytic™ MEM protein 
extraction kit (Sigma-Aldrich, St Louis, MO, USA), and the man-
ufacturer’s protocol. One microgram of the hydrophobic proteins 
or the hydrophilic proteins of each sample was labeled with 50 µg 
of Alexa Fluor (AF) 555 succinimidyl ester (Life Technologies) in 
20 µl of PBS containing 1% Triton X-100 (Sigma-Aldrich). The 
labeled proteins were purified using Zeba™ desalt spin columns 
(7K MWCO, Thermo Scientific, Waltham, MA, USA). The con-
centration of the purified proteins was adjusted to 500 ng/ml with 
Probing solution (GPBiosciences, Yokohama, Japan) to form chip-
ready samples. LecChip™ lectin microarray chips consisting of 
45 selected lectins (Supplementary information, Table S1) that ex-
hibit binding specificities for a variety of different oligosaccharide 
structures were incubated with 100 µl of the chip-ready samples 
at 4 °C for 16 h. Before scanning the chips with GlycoStation™ 
Reader 1200 (GPBiosciences), the samples on the chips were re-www.cell-research.com | Cell Research
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placed with 100 µl of fresh probing solution. Image digitizing and 
integration of fluorescence intensities of lectin spots from each 
sample were conducted using Signal Capture1.0 and Glycosta-
tion Tool Pro1.0. Since the lectin DSA has a broad specificity to 
oligosaccharide structures of (GlcNAcβ1-4)n and Galβ1-4 GlcNAc 
commonly existing in bi-, tri- and tetra-antennary complexes of N-
liked glycans and generates strong and relatively unchanged fluo-
rescence intensities in most of the tested cells, we chose DSA as 
the standard to normalize the fluorescence intensities of 45 lectins 
among all samples. Hierarchical clustering analysis to determine 
the similarity in regard to the glycoprotein compositions among 
cells was performed using NIA Array Analysis Tool (National In-
stitute on Aging, http://lgsun.grc.nia.nih.gov/ANOVA/index.html). 
Student’s t test was used as the statistical method to identify the 
lectins showing significant binding specificity between different 
cell types.
Fluorescence staining of cells with specific lectins and anti-
bodies
Lectins AOL (Tokyo Chemical Industry, Japan), and TJA-II 
(Seikagaku Biobusiness, Japan) were subjected to biotinylation us-
ing biotin-XX succinimidyl ester (Life Technologies). Biotinylated 
lectin UEA-I was purchased from Vector Laboratories (Burlingame, 
CA, USA). The harvested cells were resuspended in HBSS, evenly 
distributed on adhesion slides according to Prof. Bross (Marienfeld, 
Lauda-Königshofen, Germany) at 4 °C for 40 min to allow cells 
to attach to the slides, and then fixed in PBS containing 4% para-
formaldehyde for 25 min. The cells were incubated with 6.5 µg/ml 
biotinylated lectins, which were pre-reacted with streptavidin-AF 
488 (Life Technologies) in PBS containing 2% bovine serum albu-
min (BSA; Jackson ImmunoResearch, West Grove, PA, USA) at 
4 °C overnight. The lectin-stained cells were permeabilized using 
0.2% Triton X-100 in PBS and incubated with primary antibodies 
against specific pluripotent biomarkers and fluorophore-conjugated 
secondary antibodies. For staining for pluripotency biomarkers in 
iPS1.HEMd cells, colonies of the cells grown on MEF feeder cell-
covered coverslips were fixed and permeabilized and incubated 
with primary antibodies against specific pluripotency biomarkers 
and fluorophore-conjugated secondary antibodies. For staining 
cells differentiated into each germ layer by EB formation, pluri-
potent cell colonies were harvested and cultured in ultra low-
attachment plates with FGF-deficient DMEM/F12 medium with l-
glutamine containing 20% KnockOut™ Serum Replacement, 100 
µM non-essential amino acids, and 100 µM β-mercaptoethanol (all 
from Life Technologies) for 7 days. The medium was changed ev-
ery other day. On day 8, EBs were transferred onto gelatin-coated 
coverslips and cultured in the same medium for an additional 7 
days. EBs were then fixed, permeabilized, and incubated with an-
tibodies against biomarkers relevant to the three germ layers. The 
primary antibodies used in the study were purchased from Santa 
Cruz (POU5F1 and SOX2), Millipore (SMA, Tra-1-60 and AFP), 
R&D Systems (SSEA-4 and SOX17), Stemgent (Tra-1-81), and 
Novus Biologicals (NG2).
Teratoma formation and histopathology
Teratomas were generated in the testis capsule according to 
published protocols [41] with minor modifications. Specifically, 
iPS1.HEMd cells were harvested using Accutase
® (Life Technolo-
gies) and re-suspended in a 1:1 mixture of DMEM/F12 medium 
and Matrigel™ (BD Biosciences, San Diego, CA, USA). One mil-
lion cells were injected into the right testis of each of two mice. 
H&E-stained, 4-µm sections of the tumors from two animals were 
evaluated microscopically by a pathologist to detect derivatives 
of the three germ layers. All animal procedures were performed in 
accordance with protocols approved by the IACUC of the Scripps 
Research Institute.
Lectin-mediated cell separation
Depletion of pluripotent cells from mixed cell populations was 
performed according to the following procedure. WA09 hESCs 
were mixed with HDFs or HEMd cells at a ratio of 1:1 to form a 
mixed cell population consisting of 1 × 10
6 cells in total. R-Olig2 
hESCs were mixed with their differentiated NSC derivatives at the 
same ratio. The non-pluripotent cells were pre-labeled by 0.5 µg/
ml Calcein AM (Life Technologies) in culture medium for 20 min 
before being mixed with the pluripotent cells. Mixed populations 
were incubated in biotinylated UEA-I lectin at 4 °C for 45 min, 
followed by addition of submicron anti-biotin beads (Miltenyi 
Biotec, Auburn, CA, USA) in HBSS containing 2% BSA accord-
ing to the manufacturer’s protocol. The cells captured by the mag-
netic beads were removed from the population using MACS LS 
Magnetic Columns (Miltenyi Biotec) to harvest the beads from the 
cell suspension. Residual populations were analyzed using flow 
cytometry as described below.
To isolate viable pluripotent cells from mixtures with fibro-
blasts, biotinylated UEA-I lectin was pre-incubated with strepta-
vidin-conjugated magnetic beads (CELLection Biotin Binder 
Dynabeads; Life Technologies) to form UEA-I-magnetic beads. 
WA09 hESCs were mixed with HDFs at a ratio of 1:1 to form a 
mixed cell population consisting of 5 × 10
5 cells in total. HDFs 
were prelabeled with Calcein AM as described above. The mixed 
cells were resuspended in DMEM/F12 medium plus GlutaMax™-I 
(Life Technologies) containing 20 ng/ml FGF2 (Stemgent), 2% 
BSA, 100 µM β-mercaptoethanol (Life Technologies) and 25 µM 
phenylbenzodioxane carboximide (ROCK II inhibitor; Stemgent) 
and incubated with the UEA-I-magnetic beads at 4 °C for 3 h with 
continuous stirring. The cells captured by the magnetic beads were 
isolated using MagSweeper (Illumina, Hayward, CA, USA) to 
harvest the beads from the cell suspension. DNA linkers between 
streptavidin and beads were digested by DNase I to release the 
cells. The cells captured by the beads and the unbound cells left 
in the supernatant were resuspended separately in complete Stem-
Pro
® hESC serum-free medium (Life Technologies) and placed 
onto plates coated with Geltrex™ matrix (Life Technologies) for 
overnight incubation to allow attachment of the viable cells.
Flow cytometry
For detection of residual pluripotent cells in the mixed cell pop-
ulations subjected to pluripotent cell depletion, cell suspensions 
containing uncaptured cells were analyzed using a FACSCalibur 
flow cytometer (BD Biosciences) to detect Calcein AM fluores-
cence. For quantification of lectin binding specificity for hPSCs, 5 
× 10
5 cells were reacted with 6.5 µg/ml UEA-I-biotin followed by 
streptavidin-AF 555 in HBSS containing 2% BSA. The cells were 
subsequently counter-stained with SSEA-4 antibody or were left 
unstained as controls. The cells were analyzed using a FACSCali-
bur flow cytometer to detect fluorescence intensity associated with 
the cells.Lectin biomarkers of pluripotency
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Expression profiling of glycosyltransferases by gene expres-
sion microarray
Glycosyltransferase gene expression was analyzed according 
to published reports [42], except that array data were normalized 
using the LUMI package in R with the robust spline normalization 
method. For differential gene expression analysis, the criterion to 
estimate meaningful differences was expression level differences 
being greater than 1.4-fold at a significance level of αFDR < 0.01.
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